BACKGROUND: Chronic lung allograft dysfunction (CLAD) remains the leading cause of mortality after lung transplantation. METHODS: In this retrospective single-center study, we aimed to identify different phenotypes of and risk factors for mortality after CLAD diagnosis using univariate and multivariate Cox proportional hazard survival regression analysis. RESULTS: CLAD was diagnosed in 71 of 294 patients (24.2%) at 30.9±22.8 months after transplantation. Pulmonary function was obstructive in 51 (71.8%) of the CLAD patients, restrictive in 20 (28.2%) patients, of whom 17 had persistent parenchymal infiltrates on pulmonary computer tomography (CAT) scan. In univariate analysis, previous development of neutrophilic reversible allograft dysfunction (NRAD, P=0.012) and a restrictive pulmonary function (P=0.0024) were associated with a worse survival, whereas there was a strong trend for early development of CLAD and persistent parenchymal infiltrates on CAT scan (P=0.067 and 0.056, respectively). In multivariate analysis, early development of CLAD (P=0.0067), previous development of NRAD (P=0.0016), and a restrictive pulmonary function pattern (P=0.0005) or persistent parenchymal infiltrates on CAT scan (P=0.0043) remained significant. CONCLUSION: Although most CLAD patients develop an obstructive pulmonary function, 28% develop a restrictive pulmonary function, compatible with the recently defined restrictive allograft syndrome phenotype. Early-onset CLAD, previous development of NRAD, and the development of restrictive allograft syndrome are associated with worse survival after CLAD has been diagnosed.
BACKGROUND:Chronic lung allograft dysfunction (CLAD) remains the leading cause of mortality after lung transplantation. METHODS: In this retrospective single-center study, we aimed to identify different phenotypes of and risk factors for mortality after CLAD diagnosis using univariate and multivariate Cox proportional hazard survival regression analysis. RESULTS: CLAD was diagnosed in 71 of 294 patients (24.2%) at 30.9±22.8 months after transplantation. Pulmonary function was obstructive in 51 (71.8%) of the CLAD patients, restrictive in 20 (28.2%) patients, of whom 17 had persistent parenchymal infiltrates on pulmonary computer tomography (CAT) scan. In univariate analysis, previous development of neutrophilic reversible allograft dysfunction (NRAD, P=0.012) and a restrictive pulmonary function (P=0.0024) were associated with a worse survival, whereas there was a strong trend for early development of CLAD and persistent parenchymal infiltrates on CAT scan (P=0.067 and 0.056, respectively). In multivariate analysis, early development of CLAD (P=0.0067), previous development of NRAD (P=0.0016), and a restrictive pulmonary function pattern (P=0.0005) or persistent parenchymal infiltrates on CAT scan (P=0.0043) remained significant. CONCLUSION: Although most CLAD patients develop an obstructive pulmonary function, 28% develop a restrictive pulmonary function, compatible with the recently defined restrictive allograft syndrome phenotype. Early-onset CLAD, previous development of NRAD, and the development of restrictive allograft syndrome are associated with worse survival after CLAD has been diagnosed.
Authors: M Mansh; M Binstock; K Williams; F Hafeez; J Kim; D Glidden; R Boettger; S Hays; J Kukreja; J Golden; M M Asgari; P Chin-Hong; J P Singer; S T Arron Journal: Am J Transplant Date: 2015-09-03 Impact factor: 8.086
Authors: Hrishikesh S Kulkarni; Wida S Cherikh; Daniel C Chambers; Victoria C Garcia; Ramsey R Hachem; Daniel Kreisel; Varun Puri; Benjamin D Kozower; Derek E Byers; Chad A Witt; Jennifer Alexander-Brett; Patrick R Aguilar; Laneshia K Tague; Yuka Furuya; G Alec Patterson; Elbert P Trulock; Roger D Yusen Journal: J Heart Lung Transplant Date: 2018-09-25 Impact factor: 10.247
Authors: Adriana Dubbeldam; Caroline Barthels; Johan Coolen; Johny A Verschakelen; Stijn E Verleden; Robin Vos; Geert M Verleden; Walter De Wever Journal: Eur Radiol Date: 2016-11-22 Impact factor: 5.315
Authors: Michael P Combs; Meng Xia; David S Wheeler; Elizabeth A Belloli; Natalie M Walker; Russell R Braeuer; Dennis M Lyu; Susan Murray; Vibha N Lama Journal: J Heart Lung Transplant Date: 2020-04-19 Impact factor: 10.247
Authors: Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld Journal: Dtsch Arztebl Int Date: 2014-02-14 Impact factor: 5.594
Authors: S E Verleden; J L Todd; M Sato; S M Palmer; T Martinu; E N Pavlisko; R Vos; A Neyrinck; D Van Raemdonck; T Saito; H Oishi; S Keshavjee; M Greer; G Warnecke; J Gottlieb; A Haverich Journal: Am J Transplant Date: 2015-04-30 Impact factor: 8.086
Authors: Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer Journal: Am J Respir Crit Care Med Date: 2014-01-15 Impact factor: 21.405